Cabozantinib (Cabometyx®) is one of the most recently approved therapies for the treatment of advanced kidney cancer (Oct. 2019).
Cabozantinib is a form of tyrosine kinase inhibitor, similar to Sunitinib (Sutent®), and works by depriving cancerous cells of the oxygen and nutrients they need to grow and divide. This kind of treatment is also commonly referred to as a “VEGF inhibitor”.
In this trial, the researchers will be investigating the combination of Cabozantinib with another drug called Atezolizumab (Tecentriq®).
Atezolizumab is a form of immunotherapy that is similar to a number of already approved kidney cancer medications, such as Nivolumab (Opdivo®). In essence, Atezolizumab works by removing the “shield” that protects cancer cells from the immune system, allowing your body to reactivate its own defences to attack and destroy cancer cells. It does this by targeting a molecule called PD-L1.
This study will have two treatment groups that will be randomly assigned by the physician handling your care:
Group 1: Cabozantinib alone
Group 2: Cabozantinib in combination with Atezolizumab
In order to maximize effectiveness and minimize side effects, different doses of each drug will be used to determine the optimal dosage of these medications.
There is no control group in the study, so there will be no “placebo”, and all patients will receive treatment.
- All subtypes are eligible
- Advanced kidney cancer that cannot be removed by surgery
- Must have received prior immunotherapy treatment (this must be the most recent treatment)
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreCancer Care Manitoba||Principal InvestigatorNot given||LocationWinnipeg, MB||Trial StatusNot yet recruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Center||Principal InvestigatorNot given||LocationToronto, ON||Trial StatusRecruiting|